ENLV vs. ANIX, SRZN, CRDL, XBIT, VTGN, VIRI, IMUX, ABOS, EPIX, and CELU
Should you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Anixa Biosciences (ANIX), Surrozen (SRZN), Cardiol Therapeutics (CRDL), XBiotech (XBIT), VistaGen Therapeutics (VTGN), Virios Therapeutics (VIRI), Immunic (IMUX), Acumen Pharmaceuticals (ABOS), ESSA Pharma (EPIX), and Celularity (CELU). These companies are all part of the "pharmaceutical products" industry.
Enlivex Therapeutics vs. Its Competitors
Enlivex Therapeutics (NASDAQ:ENLV) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.
Enlivex Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500.
Anixa Biosciences has higher revenue and earnings than Enlivex Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Anixa Biosciences had 1 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 3 mentions for Anixa Biosciences and 2 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.62 beat Anixa Biosciences' score of -0.04 indicating that Enlivex Therapeutics is being referred to more favorably in the media.
Enlivex Therapeutics' return on equity of -57.67% beat Anixa Biosciences' return on equity.
1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by insiders. Comparatively, 25.3% of Anixa Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Enlivex Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 817.43%. Anixa Biosciences has a consensus target price of $9.00, suggesting a potential upside of 205.08%. Given Enlivex Therapeutics' higher possible upside, equities analysts plainly believe Enlivex Therapeutics is more favorable than Anixa Biosciences.
Summary
Anixa Biosciences beats Enlivex Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Enlivex Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enlivex Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ENLV) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access